Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garth Powis

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|April 18, 2003
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analoguesEmmanuelle J Meuillet, Daruka Mahadevan, Hariprasad Vankayalapati, et al.
Molecular Cancer Therapeutics|January 19, 2008
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alphaMei Y Koh, Taly Spivak-Kroizman, Sara Venturini, et al.
Molecular Cancer Therapeutics|September 4, 2007
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional culturesAmy L Howes, Gary G Chiang, Elizabeth S Lang, et al.
Chemical Science|December 6, 2019
Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samplesMarcin Poreba, Katarzyna Groborz, Matej Vizovisek, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 29, 2020
A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase AEun Jeong Cho, Ashwini K Devkota, Gabriel Stancu, et al.
Neuro-Oncology|March 25, 2011
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBMYong-Wan Kim, Ta Jen Liu, Dimpy Koul, et al.
The Journal of Laboratory and Clinical Medicine|February 7, 2006
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker, Tomislav Dragovich, Wendy R Tate, et al.
Nano Research|January 7, 2010
In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNAGeoffrey Bartholomeusz, Paul Cherukuri, John Kingston, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress responseAmanda F Baker, Terry Landowski, Robert Dorr, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|April 18, 2003
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analoguesEmmanuelle J Meuillet, Daruka Mahadevan, Hariprasad Vankayalapati, et al.
Molecular Cancer Therapeutics|January 19, 2008
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alphaMei Y Koh, Taly Spivak-Kroizman, Sara Venturini, et al.
Molecular Cancer Therapeutics|September 4, 2007
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional culturesAmy L Howes, Gary G Chiang, Elizabeth S Lang, et al.
Chemical Science|December 6, 2019
Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samplesMarcin Poreba, Katarzyna Groborz, Matej Vizovisek, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 29, 2020
A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase AEun Jeong Cho, Ashwini K Devkota, Gabriel Stancu, et al.
Neuro-Oncology|March 25, 2011
Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBMYong-Wan Kim, Ta Jen Liu, Dimpy Koul, et al.
The Journal of Laboratory and Clinical Medicine|February 7, 2006
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker, Tomislav Dragovich, Wendy R Tate, et al.
Nano Research|January 7, 2010
In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNAGeoffrey Bartholomeusz, Paul Cherukuri, John Kingston, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress responseAmanda F Baker, Terry Landowski, Robert Dorr, et al.
Pageof 10